← 產業報告目錄

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease [TB, HAI, STD], Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx [RT-PCR, INAAT]), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-07-10頁數 548報告編號 MD2702

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The Point of Care Diagnostics market is projected to reach USD 31.46 billion by 2031 from USD 20.63 billion in 2026, growing at a CAGR of 8.8%. Continuous technological advancements and the growing demand for rapid, accurate, and decentralized testing are driving growth in the point-of-care diagnostics market. Biochemistry technology accounts for the largest market share due to its widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing, and other routine diagnostic applications across hospitals, clinical laboratories, emergency departments, and physician offices. Its broad clinical utility, cost-effectiveness, and ability to deliver rapid results make it the preferred technology for high-volume point-of-care testing. Meanwhile, molecular diagnostics is projected to grow the fastest, owing to the increasing adoption of rapid PCR-based platforms for infectious disease detection, antimicrobial resistance testing, and outbreak preparedness. Continuous innovations in immunoassays, molecular platforms, microfluidics, multiplex testing, and portable analyzers are improving diagnostic accuracy, reducing turnaround time, and expanding testing beyond traditional laboratories. These advancements are accelerating the adoption of next-generation point-of-care diagnostic technologies across hospitals, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings, thereby creating sustained global demand for advanced diagnostic solutions. Based on product: Infectious disease testing products are projected to register the highest growth during the forecast period. The segment's dominance is driven by the increasing burden of infectious diseases, the growing demand for rapid, accurate near-patient diagnosis, and the need for timely clinical decision-making to support effective treatment and infection control. The growing adoption of point-of-care testing across hospitals, emergency departments, physicians' offices, retail clinics, pharmacies, and home healthcare settings, coupled with expanding government initiatives for infectious disease surveillance and decentralized healthcare delivery, continues to strengthen the market position of infectious disease testing products. Based on end user: Clinical laboratories account for the largest share of the point-of-care diagnostics market due to their central role in delivering rapid and accurate diagnostic testing for both acute and chronic diseases. These facilities routinely perform point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring, and clinical chemistry, supporting timely diagnosis and treatment decisions. Their extensive testing capabilities, skilled laboratory personnel, established quality management systems, and seamless integration with hospital workflows continue to drive demand for point-of-care diagnostic solutions. Furthermore, increasing test volumes, the growing emphasis on faster turnaround times, and the expanding adoption of decentralized testing within laboratory networks reinforce the dominance of clinical laboratories in the global point-of-care diagnostics market. North America accounts for the largest share of the point-of-care diagnostics market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread adoption of decentralized diagnostic testing. The region has an extensive network of hospitals, clinical laboratories, physicians' offices, urgent care centers, retail clinics, and pharmacies that routinely use point-of-care diagnostics to rapidly detect and manage infectious diseases, diabetes, cardiovascular disorders, and respiratory conditions. High healthcare expenditure, a strong presence of leading diagnostic manufacturers, and favorable regulatory support have accelerated the adoption of point-of-care testing across the U.S. and Canada. Furthermore, increasing emphasis on early diagnosis, improved patient outcomes, and reducing healthcare costs through near-patient testing continues to reinforce North America's leadership in the global point-of-care diagnostics market. A breakdown of the primary respondents (supply-side) for the POC diagnostics s market referred to in this report is provided below: • By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30% • By Designation: C-level: 55%, Director Level: 27%, and Others: 18% • By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6%, and Middle East & Africa: 3% Prominent players in the global point-of-care diagnostics market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMérieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden), and Bio-Rad Laboratories, Inc. (US) among others. Research Coverage The report evaluates the POC diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies. Reasons to Buy the Report The report will assist market leaders and new entrants in the POC diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the POC diagnostics market. This report provides insights into the following points: • Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases requiring rapid diagnosis, growing demand for decentralized and near-patient testing to enable faster clinical decision-making, increasing adoption of portable and user-friendly diagnostic devices in hospitals, clinics, and home care settings, technological advancements in microfluidics, biosensors, AI-enabled diagnostics, and smartphone-integrated testing solutions), restraints (high cost of advanced point-of-care diagnostic devices and consumables, stringent regulatory approval and quality compliance requirements, limited accuracy of certain rapid tests compared to centralized laboratory testing, data security and interoperability concerns with connected diagnostic systems), opportunities (expansion of point-of-care testing in emerging markets, increasing demand for home-based diagnostic kits and self-testing solutions, growing adoption of multiplex and molecular point-of-care diagnostics, rising investments in digital health, telemedicine, and AI-powered diagnostic platforms), and challenges (limited healthcare infrastructure and trained personnel in low-resource settings, reimbursement and pricing pressures, supply chain constraints for diagnostic reagents and consumables, standardization and integration of point-of-care diagnostic data with electronic health record systems) • Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global POC diagnostics market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by product, sample, mode of purchase, technology, end user, and region. • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global POC diagnostics market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global POC diagnostics market.
目錄 Table of Contents
1 INTRODUCTION 48 1.1 STUDY OBJECTIVES 48 1.2 MARKET DEFINITION 48 1.3 STUDY SCOPE 49 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 49 1.3.2 INCLUSIONS AND EXCLUSIONS 50 1.3.3 YEARS CONSIDERED 51 1.3.4 CURRENCY CONSIDERED 52 1.4 STAKEHOLDERS 52 1.5 SUMMARY OF CHANGES 52 2 EXECUTIVE SUMMARY 54 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 54 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 55 2.3 DISRUPTIVE TRENDS SHAPING MARKET 56 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 57 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 58 3 PREMIUM INSIGHTS 60 3.1 POC DIAGNOSTICS MARKET OVERVIEW 60 3.2 POC DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031 61 3.3 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2026 VS. 2031 61 3.4 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 62 3.5 POC DIAGNOSTICS MARKET, BY SAMPLE, 2026 VS. 2031 62 3.6 POC DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 63 3.7 POC DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63 4 MARKET OVERVIEW 64 4.1 INTRODUCTION 64 4.2 MARKET DYNAMICS 64 4.2.1 DRIVERS 65 4.2.1.1 Growing incidence of infectious diseases 65 4.2.1.2 Increasing prevalence of chronic diseases 67 4.2.1.3 Favorable government initiatives for POC testing 68 4.2.1.4 Rising number of waived tests 69 4.2.2 RESTRAINTS 70 4.2.2.1 Pricing pressure on manufacturers 70 4.2.2.2 Stringent regulatory approval process for product commercialization 71 4.2.3 OPPORTUNITIES 71 4.2.3.1 Increasing growth potential in emerging markets 71 4.2.3.2 Rising inclination toward decentralized healthcare systems 72 4.2.3.3 Booming healthcare spending worldwide 72 4.2.4 CHALLENGES 73 4.2.4.1 Inadequate standardization with centralized lab methods 73 4.2.4.2 Premium pricing of novel platforms 74 4.3 UNMET NEEDS AND WHITE SPACES 74 4.3.1 UNMET NEEDS IN POC DIAGNOSTICS MARKET 74 4.3.2 WHITE SPACE OPPORTUNITIES 75 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 76 4.4.1 INTERCONNECTED MARKETS 76 4.4.2 CROSS-SECTOR OPPORTUNITIES 78 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 79 4.5.1 KEY MOVES AND STRATEGIC FOCUS 79 5 INDUSTRY TRENDS 80 5.1 PORTER’S FIVE FORCES ANALYSIS 80 5.1.1 BARGAINING POWER OF SUPPLIERS 81 5.1.2 BARGAINING POWER OF BUYERS 81 5.1.3 THREAT OF NEW ENTRANTS 81 5.1.4 THREAT OF SUBSTITUTES 81 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81 5.2 MACROECONOMIC INDICATORS 82 5.2.1 INTRODUCTION 82 5.2.2 GDP TRENDS AND FORECAST 82 5.3 SUPPLY CHAIN ANALYSIS 85 5.4 ECOSYSTEM ANALYSIS 86 5.5 INVESTMENT AND FUNDING SCENARIO 88 5.6 PRICING ANALYSIS 89 5.6.1 AVERAGE SELLING PRICE, BY PRODUCT 89 5.6.1.1 Average selling price OF glucose monitoring test strips, by key player 90 5.6.2 AVERAGE SELLING PRICE, BY REGION 90 5.6.2.1 Average selling price of glucose monitoring test strips, by region 90 5.6.2.2 Average selling price of infectious disease testing products, by region 91 5.6.2.3 Average selling price of cardiometabolic monitoring products, by region 92 5.7 VALUE CHAIN ANALYSIS 93 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94 5.9 IMPACT OF US TARIFFS—POC DIAGNOSTICS MARKET 95 5.9.1 INTRODUCTION 95 5.9.2 KEY TARIFF RATES 96 5.9.3 PRICE IMPACT ANALYSIS 96 5.9.4 IMPACT ON COUNTRIES/REGIONS 97 5.9.4.1 North America 97 5.9.4.2 Europe 97 5.9.4.3 Asia Pacific 97 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98 6.1 KEY EMERGING TECHNOLOGIES 98 6.1.1 IMMUNOASSAYS 98 6.2 COMPLEMENTARY TECHNOLOGIES 98 6.2.1 MOLECULAR DIAGNOSTICS 98 6.3 ADJACENT TECHNOLOGIES 99 6.3.1 BIOCHEMICAL TECHNOLOGIES 99 6.4 TECHNOLOGY/PRODUCT ROADMAP 100 6.5 PATENT ANALYSIS 101 6.5.1 LIST OF MAJOR PATENTS 102 6.6 FUTURE APPLICATIONS 102 6.7 IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET 103 6.7.1 INTRODUCTION 103 6.7.2 TOP USE CASES AND MARKET POTENTIAL 104 6.7.3 KEY COMPANIES IMPLEMENTING AI 104 6.7.4 FUTURE OF AI 106 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 107 7.1 REGIONAL REGULATIONS AND COMPLIANCE 107 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 7.1.2 INDUSTRY STANDARDS 109 7.2 SUSTAINABILITY INITIATIVES 111 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS 111 7.2.1.1 Eco-friendly Initiatives 111 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 112 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113 8.1 DECISION-MAKING PROCESS 113 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 113 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113 8.2.2 BUYING CRITERIA 114 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 115 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116 8.5 MARKET PROFITABILITY 117 8.5.1 REVENUE POTENTIAL 117 8.5.2 COST DYNAMICS 117 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 118 9 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY 119 9.1 INTRODUCTION 120 9.2 BIOCHEMISTRY 120 9.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH 120 9.3 IMMUNOASSAYS 123 9.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET 123 9.4 MOLECULAR DIAGNOSTICS 127 9.4.1 RT-PCR 130 9.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market 130 9.4.2 INAAT 132 9.4.2.1 Emerging new pathogens to facilitate growth 132 10 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE 135 10.1 INTRODUCTION 136 10.2 BLOOD SAMPLES 136 10.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET 136 10.3 NASAL & OROPHARYNGEAL SWABS 140 10.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH 140 10.4 URINE SAMPLES 143 10.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET 143 10.5 OTHER SAMPLES 146 11 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 150 11.1 INTRODUCTION 151 11.2 PRESCRIPTION-BASED TESTING PRODUCTS 151 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 151 11.3 OTC TESTING PRODUCTS 155 11.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET 155 12 POINT OF CARE DIAGNOSTICS MARKET, BY END USER 159 12.1 INTRODUCTION 160 12.2 CLINICAL LABORATORIES 160 12.2.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET 160 12.3 HOME CARE SETTINGS & SELF-TESTING 163 12.3.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH 163 12.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 165 12.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH 165 12.5 AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES 168 12.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH 168 12.6 OTHER END USERS 171 13 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT 174 13.1 INTRODUCTION 175 13.2 GLUCOSE MONITORING PRODUCTS 176 13.2.1 GLUCOSE MONITORING STRIPS 178 13.2.1.1 Growing trend toward preventive healthcare to drive market 178 13.2.2 GLUCOSE MONITORING METERS 181 13.2.2.1 Growing technological advancements in glucose meters to propel market 181 13.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES 184 13.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth 184 13.3 CARDIOMETABOLIC TESTING PRODUCTS 186 13.3.1 CARDIAC MARKER TESTING PRODUCTS 190 13.3.1.1 Growing government support for cardiovascular diseases to drive market 190 13.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 192 13.3.2.1 Need to optimize hospital workflow to favor growth 192 13.3.3 HBA1C TESTING PRODUCTS 195 13.3.3.1 Increasing recommendations by government healthcare authorities to boost market 195 13.4 INFECTIOUS DISEASE TESTING PRODUCTS 197 13.4.1 RESPIRATORY INFECTION TESTING PRODUCTS 200 13.4.1.1 Influenza testing products 203 13.4.1.1.1 Need for targeted treatments to expedite growth 203 13.4.1.2 Tuberculosis testing products 206 13.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth 206 13.4.1.3 Other respiratory infection testing products 208 13.4.2 HAI TESTING PRODUCTS 211 13.4.2.1 Growing rate of surgical-site infections to boost market 211 13.4.3 TROPICAL DISEASE TESTING PRODUCTS 214 13.4.3.1 Rising incidence of malaria and dengue to support growth 214 13.4.4 STD TESTING PRODUCTS 216 13.4.4.1 HIV testing products 219 13.4.4.1.1 Growing availability and awareness of testing products to boost market 219 13.4.4.2 Hepatitis testing products 222 13.4.4.2.1 Hepatitis B testing products 224 13.4.4.2.1.1 Increasing prevalence of liver infections to favor growth 224 13.4.4.2.2 Hepatitis C testing products 227 13.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth 227 13.4.4.3 Syphilis testing products 229 13.4.4.3.1 Need for early and accessible diagnosis to expedite growth 229 13.4.4.4 Human papillomavirus testing products 232 13.4.4.4.1 Rising cases of cervical cancer to promote growth 232 13.4.4.5 Chlamydia trachomatis testing products 235 13.4.4.5.1 Growing adoption of advanced techniques to drive market 235 13.4.4.6 Neisseria gonorrhea testing products 238 13.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth 238 13.4.4.7 HSV testing products 240 13.4.4.7.1 Increasing incidence of herpes to support growth 240 13.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS 243 13.4.5.1 Rising cases among hospitalized patients to boost demand 243 13.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 245 13.5 COAGULATION MONITORING PRODUCTS 248 13.5.1 NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET 248 13.5.2 PT/INR TESTING PRODUCTS 251 13.5.2.1 Increasing number of atrial fibrillation cases to accelerate growth 251 13.5.3 ACT/APTT TESTING PRODUCTS 253 13.5.3.1 Rise in surgical procedures to speed up growth 253 13.6 PREGNANCY & FERTILITY TESTING PRODUCTS 255 13.6.1 PREGNANCY TESTING PRODUCTS 257 13.6.1.1 Increasing awareness about family planning to stimulate growth 257 13.6.2 FERTILITY TESTING PRODUCTS 260 13.6.2.1 Growing infertility issues to fuel market 260 13.7 TUMOR/CANCER MARKER TESTING PRODUCTS 263 13.7.1 GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET 263 13.8 URINALYSIS TESTING PRODUCTS 266 13.8.1 INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH 266 13.9 CHOLESTEROL TESTING PRODUCTS 269 13.9.1 GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET 269 13.10 HEMATOLOGY TESTING PRODUCTS 272 13.10.1 RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION 272 13.11 DRUGS-OF-ABUSE TESTING PRODUCTS 275 13.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET 275 13.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS 278 13.12.1 GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS 278 13.13 FECAL OCCULT TESTING PRODUCTS 280 13.13.1 GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET 280 13.14 OTHER PRODUCTS 283 14 POINT OF CARE DIAGNOSTICS MARKET, BY REGION 287 14.1 INTRODUCTION 288 14.2 NORTH AMERICA 288 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 289 14.2.2 US 296 14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditure to aid growth 296 14.2.3 CANADA 302 14.2.3.1 Rising incidence of diabetes and infectious diseases to support growth 302 14.3 EUROPE 308 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 309 14.3.2 GERMANY 316 14.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth 316 14.3.3 FRANCE 322 14.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market 322 14.3.4 UK 328 14.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth 328 14.3.5 ITALY 334 14.3.5.1 Growing burden of infectious and parasitic diseases to boost market 334 14.3.6 SPAIN 340 14.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth 340 14.3.7 REST OF EUROPE 346 14.4 ASIA PACIFIC 352 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 352 14.4.2 CHINA 359 14.4.2.1 Increasing impact of diabetes on public health to amplify growth 359 14.4.3 JAPAN 365 14.4.3.1 Booming geriatric population to stimulate growth 365 14.4.4 INDIA 371 14.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth 371 14.4.5 AUSTRALIA 378 14.4.5.1 Growing research investments for next-gen POC devices to boost market 378 14.4.6 SOUTH KOREA 384 14.4.6.1 Growing focus on innovative diagnostic products to drive market 384 14.4.7 REST OF ASIA PACIFIC 390 14.5 LATIN AMERICA 395 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 396 14.5.2 BRAZIL 402 14.5.2.1 Increasing public initiatives in healthcare to encourage growth 402 14.5.3 MEXICO 408 14.5.3.1 Need for frequent testing for disease management to expedite growth 408 14.5.4 REST OF LATIN AMERICA 414 14.6 MIDDLE EAST & AFRICA 420 14.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET 420 14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 420 15 COMPETITIVE LANDSCAPE 426 15.1 INTRODUCTION 426 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 426 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET 426 15.3 REVENUE ANALYSIS, 2023–2025 428 15.4 MARKET SHARE ANALYSIS, 2025 429 15.5 COMPANY VALUATION AND FINANCIAL METRICS 431 15.6 BRAND/PRODUCT COMPARISON 432 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 433 15.7.1 STARS 433 15.7.2 EMERGING LEADERS 433 15.7.3 PERVASIVE PLAYERS 433 15.7.4 PARTICIPANTS 433 15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025 435 15.7.5.1 Company footprint 435 15.7.5.2 Region footprint 436 15.7.5.3 Mode of purchase footprint 437 15.7.5.4 Technology footprint 438 15.7.5.5 Sample footprint 439 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 440 15.8.1 PROGRESSIVE COMPANIES 440 15.8.2 RESPONSIVE COMPANIES 440 15.8.3 DYNAMIC COMPANIES 440 15.8.4 STARTING BLOCKS 440 15.8.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 442 15.8.5.1 Detailed list of key startups/SMEs 442 15.8.5.2 Competitive benchmarking of startups/SMEs 443 15.9 COMPETITIVE SCENARIO 444 15.9.1 PRODUCT LAUNCHES AND APPROVALS 444 16 COMPANY PROFILES 445 16.1 KEY PLAYERS 445 16.1.1 ABBOTT 445 16.1.1.1 Business overview 445 16.1.1.2 Products offered 446 16.1.1.3 Recent developments 449 16.1.1.3.1 Product launches and approvals 449 16.1.1.3.2 Deals 449 16.1.1.4 MnM view 450 16.1.1.4.1 Right to win 450 16.1.1.4.2 Strategic choices 450 16.1.1.4.3 Weaknesses and competitive threats 450 16.1.2 F. HOFFMANN-LA ROCHE LTD 451 16.1.2.1 Business overview 451 16.1.2.2 Products offered 452 16.1.2.3 Recent developments 454 16.1.2.3.1 Product launches and approvals 454 16.1.2.3.2 Deals 455 16.1.2.3.3 Expansions 455 16.1.2.4 MnM view 456 16.1.2.4.1 Right to win 456 16.1.2.4.2 Strategic choices 456 16.1.2.4.3 Weaknesses and competitive threats 456 16.1.3 SIEMENS HEALTHINEERS AG 457 16.1.3.1 Business overview 457 16.1.3.2 Products offered 458 16.1.3.3 Recent developments 460 16.1.3.3.1 Product launches and approvals 460 16.1.3.3.2 Deals 460 16.1.3.3.3 Expansions 461 16.1.3.4 MnM view 462 16.1.3.4.1 Right to win 462 16.1.3.4.2 Strategic choices 462 16.1.3.4.3 Weaknesses and competitive threats 462 16.1.4 QUIDELORTHO CORPORATION 463 16.1.4.1 Business overview 463 16.1.4.2 Products offered 464 16.1.4.3 Recent developments 466 16.1.4.3.1 Product launches and approvals 466 16.1.4.3.2 Deals 467 16.1.4.3.3 Expansions 467 16.1.4.4 MnM view 467 16.1.4.4.1 Right to win 467 16.1.4.4.2 Strategic choices 468 16.1.4.4.3 Weaknesses and competitive threats 468 16.1.5 DANAHER 469 16.1.5.1 Business overview 469 16.1.5.2 Products offered 470 16.1.5.3 Recent developments 472 16.1.5.3.1 Product launches and approvals 472 16.1.5.3.2 Deals 472 16.1.5.3.3 Expansions 473 16.1.5.4 MnM view 473 16.1.5.4.1 Right to win 473 16.1.5.4.2 Strategic choices 473 16.1.5.4.3 Weaknesses and competitive threats 473 16.1.6 WERFEN 474 16.1.6.1 Business overview 474 16.1.6.2 Products offered 475 16.1.6.3 Recent developments 476 16.1.6.3.1 Product launches and approvals 476 16.1.6.3.2 Deals 476 16.1.6.3.3 Expansions 477 16.1.6.4 MnM view 477 16.1.6.4.1 Right to win 477 16.1.6.4.2 Strategic choices 477 16.1.6.4.3 Weaknesses and competitive threats 477 16.1.7 BD 478 16.1.7.1 Business overview 478 16.1.7.2 Products offered 479 16.1.7.3 Recent developments 480 16.1.7.3.1 Product launches and approvals 480 16.1.7.3.2 Deals 480 16.1.7.3.3 Expansions 481 16.1.8 THERMO FISHER SCIENTIFIC INC. 482 16.1.8.1 Business overview 482 16.1.8.2 Products offered 484 16.1.8.3 Recent developments 484 16.1.8.3.1 Deals 484 16.1.9 BIOMÉRIEUX 485 16.1.9.1 Business overview 485 16.1.9.2 Products offered 486 16.1.9.3 Recent developments 487 16.1.9.3.1 Product launches and approvals 487 16.1.9.3.2 Deals 488 16.1.10 EKF DIAGNOSTICS HOLDINGS PLC 489 16.1.10.1 Business overview 489 16.1.10.2 Products offered 490 16.1.10.3 Recent developments 491 16.1.10.3.1 Product launches and approvals 491 16.1.10.3.2 Expansions 491 16.1.10.3.3 Other developments 492 16.1.11 TRINITY BIOTECH 493 16.1.11.1 Business overview 493 16.1.11.2 Products offered 494 16.1.11.3 Recent developments 495 16.1.11.3.1 Product launches and approvals 495 16.1.11.3.2 Deals 495 16.1.12 ORASURE TECHNOLOGIES, INC. 496 16.1.12.1 Business overview 496 16.1.12.2 Products offered 497 16.1.12.3 Recent developments 498 16.1.12.3.1 Product launches and approvals 498 16.1.12.3.2 Deals 499 16.1.13 GRIFOLS S.A. 500 16.1.13.1 Business overview 500 16.1.13.2 Products offered 501 16.1.13.3 Recent developments 502 16.1.13.3.1 Product launches and approvals 502 16.1.14 QIAGEN 503 16.1.14.1 Business overview 503 16.1.14.2 Products offered 504 16.1.14.3 Recent developments 505 16.1.14.3.1 Product launches and approvals 505 16.1.14.3.2 Deals 506 16.1.14.3.3 Expansions 506 16.2 OTHER PLAYERS 507 16.2.1 NOVA BIOMEDICAL 507 16.2.1.1 Business overview 507 16.2.1.2 Products offered 507 16.2.1.3 Recent developments 508 16.2.1.3.1 Product launches and approvals 508 16.2.1.3.2 Deals 509 16.2.2 SEKISUI DIAGNOSTICS 510 16.2.2.1 Business overview 510 16.2.2.2 Products offered 510 16.2.2.3 Recent developments 511 16.2.2.3.1 Product launches and approvals 511 16.2.3 SEKISUI DIAGNOSTICS 512 16.2.3.1 Business overview 512 16.2.3.2 Products offered 512 16.2.3.3 Recent developments 513 16.2.3.3.1 Product launches and approvals 513 16.2.4 LIFESCAN IP HOLDINGS, LLC 514 16.2.5 PTS DIAGNOSTICS 515 16.2.6 EUROLYSER DIAGNOSTICA GMBH 516 16.2.7 RESPONSE BIOMEDICAL 517 16.2.8 ALFA SCIENTIFIC DESIGNS, INC. 518 16.2.9 BTNX INC. 519 16.2.10 ASCENSIA DIABETES CARE HOLDINGS AG 520 16.2.11 FLUXERGY 521 16.2.12 PRECISION BIOSENSOR, INC. 522 16.2.13 ACON LABORATORIES, INC. 523 16.2.14 MENARINI DIAGNOSTICS S.R.L 524 16.2.15 MANKIND PHARMA 525 17 RESEARCH METHODOLOGY 526 17.1 RESEARCH DATA 526 17.2 RESEARCH APPROACH 526 17.2.1 SECONDARY RESEARCH 527 17.2.1.1 Key data from secondary sources 527 17.2.2 PRIMARY DATA 528 17.2.2.1 Primary sources 529 17.2.2.2 Key data from primary sources 530 17.2.2.3 Key industry insights 531 17.3 MARKET SIZE ESTIMATION 532 17.3.1 BOTTOM-UP APPROACH 533 17.3.1.1 Approach 1: Company revenue estimation approach 533 17.3.1.2 Approach 2: Presentations of companies and primary interviews 534 17.3.1.3 Growth forecast 534 17.3.2 TOP-DOWN APPROACH 535 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 536 17.5 MARKET SHARE ANALYSIS 537 17.6 RESEARCH ASSUMPTIONS 537 17.6.1 PARAMETRIC ASSUMPTIONS 537 17.6.2 GROWTH RATE ASSUMPTIONS 538 17.7 RESEARCH LIMITATIONS 538 17.8 RISK ASSESSMENT 538 18 APPENDIX 539 18.1 DISCUSSION GUIDE 539 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 544 18.3 CUSTOMIZATION OPTIONS 546 18.4 RELATED REPORTS 546 18.5 AUTHOR DETAILS 547
圖表清單 List of Tables & Figures
TABLE 1 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2025 VS. 2035 VS. 2045 67 TABLE 2 GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION, 2024 VS. 2030 VS. 2045 (IN THOUSANDS) 68 TABLE 3 PRODUCT WAIVERS, BY KEY PLAYER, 2021–2026 70 TABLE 4 POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 81 TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031 82 TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS 83 TABLE 7 EUROPE: MACROECONOMIC INDICATORS 83 TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS 84 TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS 84 TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 84 TABLE 11 POC DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 87 TABLE 12 AVERAGE SELLING PRICE OF POC TESTS, BY PRODUCT, 2023–2025 89 TABLE 13 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023–2025 90 TABLE 14 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023–2025 90 TABLE 15 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023–2025 91 TABLE 16 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023–2025 92 TABLE 17 US-ADJUSTED RECIPROCAL TARIFF RATES 96 TABLE 18 LIST OF MAJOR PATENTS PERTAINING TO POC DIAGNOSTICS MARKET, 2023–2025 102 TABLE 19 KEY COMPANIES IMPLEMENTING AI IN POC DIAGNOSTICS MARKET 105 TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109 TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109 TABLE 25 GLOBAL STANDARDS IN POC DIAGNOSTICS MARKET 110 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%) 114 TABLE 27 KEY BUYING CRITERIA, BY TECHNOLOGY 114 TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 115 TABLE 29 POC DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116 TABLE 30 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 120 TABLE 31 KEY BIOCHEMISTRY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 121 TABLE 32 POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 33 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 34 EUROPE: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 35 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 36 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 37 KEY IMMUNOASSAY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 124 TABLE 38 POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 39 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 40 EUROPE: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 41 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 42 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 43 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 128 TABLE 44 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 45 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 46 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 47 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 48 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 49 KEY RT-PCR-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 130 TABLE 50 POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 51 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 52 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 53 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 54 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 55 KEY INAAT-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 133 TABLE 56 POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 57 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 58 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 59 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 60 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 61 POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 136 TABLE 62 KEY BLOOD SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 137 TABLE 63 POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 64 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 65 EUROPE: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 66 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 67 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 68 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 141 TABLE 69 POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 70 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 71 EUROPE: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 72 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 73 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 74 KEY URINE SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 144 TABLE 75 POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 76 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 77 EUROPE: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 78 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 79 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 80 KEY OTHER SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 147 TABLE 81 POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 82 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 83 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 84 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 85 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 86 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 151 TABLE 87 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE 152 TABLE 88 POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 89 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 90 EUROPE: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 91 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 92 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 93 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE 156 TABLE 94 POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 95 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 96 EUROPE: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 97 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 98 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 99 POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 160 TABLE 100 POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 101 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 102 EUROPE: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 103 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 104 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 105 POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 106 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 107 EUROPE: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 108 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 109 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 110 POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 111 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 112 EUROPE: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 113 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 114 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, B Y COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 115 POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 116 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 117 EUROPE: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 118 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 119 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 120 POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 121 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 122 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 123 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 124 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 125 POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 175 TABLE 126 POC GLUCOSE MONITORING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 127 POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 128 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 129 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 130 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 131 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 132 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE 179 TABLE 133 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 134 NORTH AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 135 EUROPE: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 136 ASIA PACIFIC: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 137 LATIN AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 138 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE 181 TABLE 139 GLUCOSE MONITORING METERS MARKET, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 140 NORTH AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 141 EUROPE: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 142 ASIA PACIFIC: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 143 LATIN AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 144 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE 184 TABLE 145 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 146 NORTH AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 147 EUROPE: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 148 ASIA PACIFIC: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 149 LATIN AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 150 KEY CARDIOMETABOLIC TESTING PRODUCTS AVAILABLE WORLDWIDE 187 TABLE 151 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 152 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 153 NORTH AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 154 EUROPE: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 155 ASIA PACIFIC: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 156 LATIN AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 157 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 158 NORTH AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 159 EUROPE: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 160 ASIA PACIFIC: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 161 LATIN AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 162 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 193 TABLE 163 NORTH AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 164 EUROPE: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 165 ASIA PACIFIC: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 166 LATIN AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 167 HBA1C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 196 TABLE 168 NORTH AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 169 EUROPE: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 170 ASIA PACIFIC: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 171 LATIN AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 172 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 173 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 199 TABLE 174 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 175 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 176 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 177 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 178 RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 179 RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 201 TABLE 180 NORTH AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 181 EUROPE: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 182 ASIA PACIFIC: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 183 LATIN AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 184 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE 204 TABLE 185 INFLUENZA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 204 TABLE 186 NORTH AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 187 EUROPE: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 188 ASIA PACIFIC: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 189 LATIN AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 190 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE 206 TABLE 191 TUBERCULOSIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 207 TABLE 192 NORTH AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 193 EUROPE: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 194 ASIA PACIFIC: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 195 LATIN AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 196 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE 209 TABLE 197 OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 198 NORTH AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 199 EUROPE: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 200 ASIA PACIFIC: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 201 LATIN AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 202 KEY HAI TESTING PRODUCTS AVAILABLE WORLDWIDE 212 TABLE 203 HAI TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 212 TABLE 204 NORTH AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 205 EUROPE: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 206 ASIA PACIFIC: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 207 LATIN AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 208 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE 214 TABLE 209 TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 210 NORTH AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 211 EUROPE: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 212 ASIA PACIFIC: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 213 LATIN AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 214 STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 215 STD TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 217 TABLE 216 NORTH AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 217 EUROPE: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 218 ASIA PACIFIC: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 219 LATIN AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 220 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE 219 TABLE 221 HIV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 220 TABLE 222 NORTH AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 223 EUROPE: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 224 ASIA PACIFIC: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 225 LATIN AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 226 HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 227 HEPATITIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 223 TABLE 228 NORTH AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 229 EUROPE: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 230 ASIA PACIFIC: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 231 LATIN AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 232 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE 225 TABLE 233 HEPATITIS B TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 225 TABLE 234 NORTH AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 235 EUROPE: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 236 ASIA PACIFIC: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 237 LATIN AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 238 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE 227 TABLE 239 HEPATITIS C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 228 TABLE 240 NORTH AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 241 EUROPE: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 242 ASIA PACIFIC: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 243 LATIN AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 244 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE 230 TABLE 245 SYPHILIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 230 TABLE 246 NORTH AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 247 EUROPE: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 248 ASIA PACIFIC: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 249 LATIN AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 250 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE 233 TABLE 251 HPV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 233 TABLE 252 NORTH AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 253 EUROPE: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 254 ASIA PACIFIC: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 255 LATIN AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 256 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE 236 TABLE 257 CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 236 TABLE 258 NORTH AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 259 EUROPE: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 260 ASIA PACIFIC: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 261 LATIN AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 262 NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 239 TABLE 263 NORTH AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 264 EUROPE: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 265 ASIA PACIFIC: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 266 LATIN AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 267 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE 241 TABLE 268 HSV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 241 TABLE 269 NORTH AMERICA: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241 TABLE 270 EUROPE: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242 TABLE 271 ASIA PACIFIC: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242 TABLE 272 LATIN AMERICA: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242 TABLE 273 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE 243 TABLE 274 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 243 TABLE 275 NORTH AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 276 EUROPE: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 277 ASIA PACIFIC: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 278 LATIN AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 279 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE 246 TABLE 280 OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 246 TABLE 281 NORTH AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 246 TABLE 282 EUROPE: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 283 ASIA PACIFIC: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 284 LATIN AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 285 POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 286 POC COAGULATION MONITORING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 249 TABLE 287 NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249 TABLE 288 EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 289 ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 290 LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 291 PT/INR TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 251 TABLE 292 NORTH AMERICA: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 293 EUROPE: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 294 ASIA PACIFIC: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 295 LATIN AMERICA: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 296 ACT/APTT TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 253 TABLE 297 NORTH AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 298 EUROPE: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 299 ASIA PACIFIC: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 300 LATIN AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 255 TABLE 301 POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 302 POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 256 TABLE 303 NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 304 EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 305 ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 306 LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 307 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE 258 TABLE 308 PREGNANCY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 259 TABLE 309 NORTH AMERICA: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 310 EUROPE: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 311 ASIA PACIFIC: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 312 LATIN AMERICA: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 313 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE 261 TABLE 314 FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 261 TABLE 315 NORTH AMERICA: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 316 EUROPE: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 317 ASIA PACIFIC: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 318 LATIN AMERICA: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 263 TABLE 319 TYPES OF CANCER CASES WORLDWIDE, 2024VS. 2045 264 TABLE 320 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE 264 TABLE 321 POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 265 TABLE 322 NORTH AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 323 EUROPE: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 324 ASIA PACIFIC: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 266 TABLE 325 LATIN AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 266 TABLE 326 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE 267 TABLE 327 POC URINALYSIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 268 TABLE 328 NORTH AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 329 EUROPE: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 330 ASIA PACIFIC: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 331 LATIN AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 332 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE 270 TABLE 333 POC CHOLESTEROL TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 270 TABLE 334 NORTH AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 335 EUROPE: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 336 ASIA PACIFIC: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 337 LATIN AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 338 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE 273 TABLE 339 POC HEMATOLOGY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 273 TABLE 340 NORTH AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 341 EUROPE: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 342 ASIA PACIFIC: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 343 LATIN AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 275 TABLE 344 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE 275 TABLE 345 POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 276 TABLE 346 NORTH AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276 TABLE 347 EUROPE: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 348 ASIA PACIFIC: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 349 LATIN AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 278 TABLE 350 KEY THYROID-STIMULATING HORMONE TESTING PRODUCTS AVAILABLE WORLDWIDE 278 TABLE 351 POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 279 TABLE 352 NORTH AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 353 EUROPE: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 354 ASIA PACIFIC: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 355 LATIN AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 356 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE 281 TABLE 357 POC FECAL OCCULT TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 281 TABLE 358 NORTH AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 359 EUROPE: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 360 ASIA PACIFIC: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 361 LATIN AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283 TABLE 362 OTHER KEY POC DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE 284 TABLE 363 OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 284 TABLE 364 NORTH AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 365 EUROPE: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 366 ASIA PACIFIC: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 367 LATIN AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 368 POC DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 288 TABLE 369 NORTH AMERICA: MACROECONOMIC INDICATORS 289 TABLE 370 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 290 TABLE 371 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 291 TABLE 372 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 373 NORTH AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 374 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 375 NORTH AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 376 NORTH AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 377 NORTH AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 378 NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 379 NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 380 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 294 TABLE 381 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 294 TABLE 382 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 383 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 295 TABLE 384 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 295 TABLE 385 US: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 297 TABLE 386 US: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 387 US: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 388 US: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 389 US: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 390 US: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 391 US: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 392 US: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 393 US: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 394 US: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 301 TABLE 395 US: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 301 TABLE 396 US: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 397 US: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 302 TABLE 398 US: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 302 TABLE 399 CANADA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 303 TABLE 400 CANADA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 401 CANADA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 402 CANADA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 403 CANADA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 404 CANADA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 405 CANADA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 406 CANADA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 407 CANADA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 408 CANADA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 306 TABLE 409 CANADA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 307 TABLE 410 CANADA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 411 CANADA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 307 TABLE 412 CANADA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 308 TABLE 413 EUROPE: MACROECONOMIC INDICATORS 310 TABLE 414 EUROPE: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 310 TABLE 415 EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 311 TABLE 416 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 417 EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 418 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 419 EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 420 EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 421 EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 422 EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 423 EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 424 EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 314 TABLE 425 EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 314 TABLE 426 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 427 EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 315 TABLE 428 EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 315 TABLE 429 GERMANY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 317 TABLE 430 GERMANY: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 431 GERMANY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 432 GERMANY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 433 GERMANY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 434 GERMANY: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 435 GERMANY: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 436 GERMANY: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 437 GERMANY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 438 GERMANY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 320 TABLE 439 GERMANY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 321 TABLE 440 GERMANY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 441 GERMANY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 321 TABLE 442 GERMANY: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 322 TABLE 443 FRANCE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 323 TABLE 444 FRANCE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 445 FRANCE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 446 FRANCE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 447 FRANCE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 448 FRANCE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 449 FRANCE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 450 FRANCE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 451 FRANCE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 452 FRANCE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 326 TABLE 453 FRANCE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 326 TABLE 454 FRANCE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 455 FRANCE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 327 TABLE 456 FRANCE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 327 TABLE 457 UK: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 329 TABLE 458 UK: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 459 UK: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 460 UK: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 461 UK: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 462 UK: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 463 UK: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 464 UK: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 465 UK: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 466 UK: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 332 TABLE 467 UK: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 332 TABLE 468 UK: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 469 UK: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 333 TABLE 470 UK: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 333 TABLE 471 ITALY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 335 TABLE 472 ITALY: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 473 ITALY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 474 ITALY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 475 ITALY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 476 ITALY: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 477 ITALY: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 478 ITALY: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 479 ITALY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 480 ITALY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 338 TABLE 481 ITALY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 338 TABLE 482 ITALY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 483 ITALY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 339 TABLE 484 ITALY: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 339 TABLE 485 SPAIN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 341 TABLE 486 SPAIN: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 487 SPAIN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 488 SPAIN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 489 SPAIN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 490 SPAIN: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 491 SPAIN: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 492 SPAIN: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 493 SPAIN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 494 SPAIN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 344 TABLE 495 SPAIN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 344 TABLE 496 SPAIN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 497 SPAIN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 345 TABLE 498 SPAIN: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 345 TABLE 499 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 347 TABLE 500 REST OF EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 501 REST OF EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 502 REST OF EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 503 REST OF EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 504 REST OF EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 505 REST OF EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 506 REST OF EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 507 REST OF EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 508 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 350 TABLE 509 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 350 TABLE 510 REST OF EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 511 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 351 TABLE 512 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 351 TABLE 513 ASIA PACIFIC: MACROECONOMIC INDICATORS 353 TABLE 514 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 354 TABLE 515 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 354 TABLE 516 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 517 ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 518 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 519 ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 520 ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 521 ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 522 ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 523 ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 524 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 357 TABLE 525 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 358 TABLE 526 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 358 TABLE 527 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 358 TABLE 528 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 359 TABLE 529 CHINA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 360 TABLE 530 CHINA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 531 CHINA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 532 CHINA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 533 CHINA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 534 CHINA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 535 CHINA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 536 CHINA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 537 CHINA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 538 CHINA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 363 TABLE 539 CHINA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 364 TABLE 540 CHINA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 364 TABLE 541 CHINA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 364 TABLE 542 CHINA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 365 TABLE 543 JAPAN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 366 TABLE 544 JAPAN: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 545 JAPAN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 546 JAPAN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 547 JAPAN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 548 JAPAN: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 549 JAPAN: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 550 JAPAN: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 551 JAPAN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 552 JAPAN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 369 TABLE 553 JAPAN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 370 TABLE 554 JAPAN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 370 TABLE 555 JAPAN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 370 TABLE 556 JAPAN: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 371 TABLE 557 INDIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 373 TABLE 558 INDIA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 559 INDIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 560 INDIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 561 INDIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 562 INDIA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 563 INDIA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 564 INDIA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 565 INDIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 376 TABLE 566 INDIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 376 TABLE 567 INDIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 376 TABLE 568 INDIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 377 TABLE 569 INDIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 377 TABLE 570 INDIA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 377 TABLE 571 AUSTRALIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 379 TABLE 572 AUSTRALIA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 573 AUSTRALIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 574 AUSTRALIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 575 AUSTRALIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 576 AUSTRALIA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 577 AUSTRALIA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 578 AUSTRALIA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 579 AUSTRALIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 382 TABLE 580 AUSTRALIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 382 TABLE 581 AUSTRALIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 382 TABLE 582 AUSTRALIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 383 TABLE 583 AUSTRALIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 383 TABLE 584 AUSTRALIA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 383 TABLE 585 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 385 TABLE 586 SOUTH KOREA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 587 SOUTH KOREA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 588 SOUTH KOREA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 589 SOUTH KOREA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 590 SOUTH KOREA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 591 SOUTH KOREA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 592 SOUTH KOREA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 593 SOUTH KOREA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 594 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 388 TABLE 595 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 388 TABLE 596 SOUTH KOREA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 597 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 389 TABLE 598 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 389 TABLE 599 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 390 TABLE 600 REST OF ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 601 REST OF ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 602 REST OF ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 391 TABLE 603 REST OF ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 604 REST OF ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 605 REST OF ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 606 REST OF ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 607 REST OF ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 608 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 393 TABLE 609 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 394 TABLE 610 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 611 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 394 TABLE 612 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 395 TABLE 613 LATIN AMERICA: MACROECONOMIC INDICATORS 396 TABLE 614 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 397 TABLE 615 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 397 TABLE 616 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 617 LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 618 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 619 LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 620 LATIN AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 621 LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 622 LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 623 LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 624 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 400 TABLE 625 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 401 TABLE 626 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 401 TABLE 627 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 401 TABLE 628 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 402 TABLE 629 BRAZIL: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 403 TABLE 630 BRAZIL: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 631 BRAZIL: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 632 BRAZIL: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 633 BRAZIL: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 634 BRAZIL: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 635 BRAZIL: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 636 BRAZIL: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 637 BRAZIL: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 406 TABLE 638 BRAZIL: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 406 TABLE 639 BRAZIL: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 406 TABLE 640 BRAZIL: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 407 TABLE 641 BRAZIL: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 407 TABLE 642 BRAZIL: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 407 TABLE 643 MEXICO: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 409 TABLE 644 MEXICO: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 409 TABLE 645 MEXICO: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 646 MEXICO: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 647 MEXICO: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 648 MEXICO: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 649 MEXICO: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 650 MEXICO: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 651 MEXICO: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 652 MEXICO: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 412 TABLE 653 MEXICO: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 412 TABLE 654 MEXICO: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 413 TABLE 655 MEXICO: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 413 TABLE 656 MEXICO: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 413 TABLE 657 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 415 TABLE 658 REST OF LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415 TABLE 659 REST OF LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 660 REST OF LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 661 REST OF LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 662 REST OF LATIN AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 663 REST OF LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 664 REST OF LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 665 REST OF LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 666 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 418 TABLE 667 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 418 TABLE 668 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 669 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 419 TABLE 670 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 419 TABLE 671 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 421 TABLE 672 MIDDLE EAST & AFRICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 421 TABLE 673 MIDDLE EAST & AFRICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 674 MIDDLE EAST & AFRICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 675 MIDDLE EAST & AFRICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 676 MIDDLE EAST & AFRICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 677 MIDDLE EAST & AFRICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 678 MIDDLE EAST & AFRICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 679 MIDDLE EAST & AFRICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 680 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 424 TABLE 681 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 424 TABLE 682 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 683 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 425 TABLE 684 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 425 TABLE 685 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES, JANUARY 2023–JUNE 2026 426 TABLE 686 POC DIAGNOSTICS MARKET: DEGREE OF COMPETITION 430 TABLE 687 POC DIAGNOSTICS MARKET: REGION FOOTPRINT 436 TABLE 688 POC DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT 437 TABLE 689 POC DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 438 TABLE 690 POC DIAGNOSTICS MARKET: SAMPLE FOOTPRINT 439 TABLE 691 POC DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 442 TABLE 692 POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 443 TABLE 693 POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 443 TABLE 694 POC DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2026 444 TABLE 695 ABBOTT: COMPANY OVERVIEW 445 TABLE 696 ABBOTT: PRODUCTS OFFERED 446 TABLE 697 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 449 TABLE 698 ABBOTT: DEALS, JANUARY 2023–JUNE 2026 449 TABLE 699 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 451 TABLE 700 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 452 TABLE 701 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 454 TABLE 702 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–JUNE 2026 455 TABLE 703 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–JUNE 2026 455 TABLE 704 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 457 TABLE 705 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 458 TABLE 706 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 460 TABLE 707 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–JUNE 2026 460 TABLE 708 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–JUNE 2026 461 TABLE 709 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 463 TABLE 710 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 464 TABLE 711 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 466 TABLE 712 QUIDELORTHO CORPORATION: DEALS, JANUARY 2023–JUNE 2026 467 TABLE 713 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2023–JUNE 2026 467 TABLE 714 DANAHER: COMPANY OVERVIEW 469 TABLE 715 DANAHER: PRODUCTS OFFERED 470 TABLE 716 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 472 TABLE 717 DANAHER: DEALS, JANUARY 2023–JUNE 2026 472 TABLE 718 DANAHER: EXPANSIONS, JANUARY 2023–JUNE 2026 473 TABLE 719 WERFEN: COMPANY OVERVIEW 474 TABLE 720 WERFEN: PRODUCTS OFFERED 475 TABLE 721 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 476 TABLE 722 WERFEN: DEALS, JANUARY 2023–JUNE 2026 476 TABLE 723 WERFEN: EXPANSIONS, JANUARY 2023–JUNE 2026 477 TABLE 724 BD: COMPANY OVERVIEW 478 TABLE 725 BD: PRODUCTS OFFERED 479 TABLE 726 BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 480 TABLE 727 BD: DEALS, JANUARY 2023–JUNE 2026 480 TABLE 728 BD: EXPANSIONS, JANUARY 2023–JUNE 2026 481 TABLE 729 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 482 TABLE 730 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 484 TABLE 731 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026 484 TABLE 732 BIOMÉRIEUX: COMPANY OVERVIEW 485 TABLE 733 BIOMÉRIEUX: PRODUCTS OFFERED 486 TABLE 734 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 487 TABLE 735 BIOMÉRIEUX: DEALS, JANUARY 2023–JUNE 2026 488 TABLE 736 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 489 TABLE 737 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED 490 TABLE 738 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 491 TABLE 739 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2023–JUNE 2026 491 TABLE 740 EKF DIAGNOSTICS HOLDINGS PLC: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 492 TABLE 741 TRINITY BIOTECH: COMPANY OVERVIEW 493 TABLE 742 TRINITY BIOTECH: PRODUCTS OFFERED 494 TABLE 743 TRINITY BIOTECH: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 495 TABLE 744 TRINITY BIOTECH: DEALS, JANUARY 2023–JUNE 2026 495 TABLE 745 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW 496 TABLE 746 ORASURE TECHNOLOGIES, INC.: PRODUCTS OFFERED 497 TABLE 747 ORASURE TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 498 TABLE 748 ORASURE TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JUNE 2026 499 TABLE 749 GRIFOLS S.A.: COMPANY OVERVIEW 500 TABLE 750 GRIFOLS S.A.: PRODUCTS OFFERED 501 TABLE 751 GRIFOLS S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 502 TABLE 752 QIAGEN: COMPANY OVERVIEW 503 TABLE 753 QIAGEN: PRODUCTS OFFERED 504 TABLE 754 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 505 TABLE 755 QIAGEN: DEALS, JANUARY 2023–JUNE 2026 506 TABLE 756 QIAGEN: EXPANSIONS, JANUARY 2023–JUNE 2026 506 TABLE 757 NOVA BIOMEDICAL: COMPANY OVERVIEW 507 TABLE 758 NOVA BIOMEDICAL: PRODUCTS OFFERED 507 TABLE 759 NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 508 TABLE 760 NOVA BIOMEDICAL: DEALS, JANUARY 2023–JUNE 2026 509 TABLE 761 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 510 TABLE 762 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED 510 TABLE 763 SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 511 TABLE 764 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 512 TABLE 765 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED 512 TABLE 766 SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 513 TABLE 767 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW 514 TABLE 768 PTS DIAGNOSTICS: COMPANY OVERVIEW 515 TABLE 769 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW 516 TABLE 770 RESPONSE BIOMEDICAL: COMPANY OVERVIEW 517 TABLE 771 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW 518 TABLE 772 BTNX INC.: COMPANY OVERVIEW 519 TABLE 773 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW 520 TABLE 774 FLUXERGY: COMPANY OVERVIEW 521 TABLE 775 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW 522 TABLE 776 ACON LABORATORIES, INC.: COMPANY OVERVIEW 523 TABLE 777 MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW 524 TABLE 778 MANKIND PHARMA: COMPANY OVERVIEW 525 TABLE 779 POC DIAGNOSTICS MARKET: RISK ASSESSMENT 538 FIGURE 1 POC DIAGNOSTICS MARKET SEGMENTATION 49 FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS 54 FIGURE 3 GLOBAL POC DIAGNOSTICS MARKET, 2024–2031 55 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN POC DIAGNOSTICS MARKET, 2023–2025 55 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF POC DIAGNOSTICS MARKET 56 FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN POC DIAGNOSTICS MARKET, 2026-2031 57 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 58 FIGURE 8 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 60 FIGURE 9 GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 61 FIGURE 10 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD 61 FIGURE 11 BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD 62 FIGURE 12 BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 62 FIGURE 13 HOME CARE SETTINGS & SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE 63 FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63 FIGURE 15 POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64 FIGURE 16 REGIONAL INCIDENCE OF HIV, 2025 66 FIGURE 17 POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 80 FIGURE 18 POC DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 85 FIGURE 19 POC DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 86 FIGURE 20 INVESTMENT AND FUNDING SCENARIO, 2021–2024 88 FIGURE 21 POC DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 93 FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN POC DIAGNOSTICS MARKET 95 FIGURE 23 PATENT ANALYSIS FOR POC DIAGNOSTICS 101 FIGURE 24 MARKET POTENTIAL OF AI IN POC DIAGNOSTICS MARKET 104 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY 113 FIGURE 26 KEY BUYING CRITERIA, BY TECHNOLOGY 114 FIGURE 27 NORTH AMERICA: POC DIAGNOSTICS MARKET SNAPSHOT 290 FIGURE 28 ASIA PACIFIC: POC DIAGNOSTICS MARKET SNAPSHOT 353 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN POC DIAGNOSTICS MARKET 2023–2025 429 FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 429 FIGURE 31 EV/EBITDA OF KEY VENDORS, 2024 431 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 431 FIGURE 33 POC DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON 432 FIGURE 34 POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 434 FIGURE 35 POC DIAGNOSTICS MARKET: COMPANY FOOTPRINT 435 FIGURE 36 POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 441 FIGURE 37 ABBOTT: COMPANY SNAPSHOT (2025) 446 FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 452 FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 458 FIGURE 40 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 464 FIGURE 41 DANAHER: COMPANY SNAPSHOT (2025) 470 FIGURE 42 WERFEN: COMPANY SNAPSHOT (2025) 475 FIGURE 43 BD: COMPANY SNAPSHOT (2025) 479 FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 483 FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 486 FIGURE 46 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2025) 490 FIGURE 47 TRINITY BIOTECH: COMPANY SNAPSHOT (2025) 494 FIGURE 48 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 497 FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2025) 501 FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025) 504 FIGURE 51 POC DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 526 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 531 FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 532 FIGURE 54 GLOBAL POC DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS 533 FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 534 FIGURE 56 TOP-DOWN APPROACH 535 FIGURE 57 DATA TRIANGULATION METHODOLOGY 536

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們